| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| fennel essential oil has major constituents commonly include trans-anethole, fenchone, estragole, limonene, and cis-anethole, and the proportions vary substantially by source, geography, and chemotype. One composition study found trans-anethole ranging 34.8–82.0%, fenchone 1.6–22.8%, estragole 2.4–17.0%, and limonene 0.8–16.5%. Another study found even wider variation, with estragole(toxic) reported up to 66% in some fennel oils. Fennel oil — the volatile essential oil distilled primarily from the ripe fruits of Foeniculum vulgare Mill. It is a variable botanical mixture rather than a single pharmacological agent and is formally classified as a plant-derived essential oil or phytochemical mixture. Standard abbreviations include FEO and FVO. Trans-anethole is usually the dominant constituent, with fenchone, estragole, limonene, α-pinene and smaller terpenoids present in chemotype-dependent proportions. Sweet fennel oil is generally richer in trans-anethole and lower in fenchone than bitter fennel oil. Biological effects cannot be assigned uniformly across products because constituent concentrations, especially estragole, vary substantially. Primary mechanisms (ranked):
Bioavailability / PK relevance: Fennel oil is lipophilic, volatile and compositionally variable. Trans-anethole is absorbed and extensively metabolized by side-chain oxidation, with urinary elimination dominated by 4-methoxyhippuric acid. At low dietary exposures, detoxification predominates; high continuous exposures can shift metabolism toward potentially hepatotoxic intermediates. Oral anticancer exposure, tumor distribution and a validated therapeutic plasma concentration have not been established. Encapsulation may improve stability and delivery, but remains experimental. In-vitro vs systemic exposure relevance: Most anticancer findings use concentrated essential oil or trans-anethole at micromolar concentrations, often approximately 50–200 µM, or essential-oil concentrations measured in µg/mL. These exposures are substantially higher than ordinary dietary exposure and have not been shown to be safely achievable in human tumors. Fennel tea, culinary seed intake and aromatherapy should not be treated as pharmacokinetically equivalent to concentrated essential oil. Clinical evidence status: Preclinical only for cancer treatment. Evidence consists mainly of cancer-cell studies, limited animal experiments and mechanistic studies of trans-anethole. There are no established randomized oncology trials, approved anticancer indications or validated clinical dosing regimens for fennel oil. Traditional herbal deployment is directed mainly toward mild gastrointestinal or respiratory symptoms rather than cancer. Concentrated internal use is constrained by estragole exposure, product heterogeneity, allergy risk and inadequate long-term safety data. Fennel Oil Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 6396- | ANE, | FEO, | Anethole Inhibits the Proliferation of Human Prostate Cancer Cells via Induction of Cell Cycle Arrest and Apoptosis |
| - | in-vitro, | Pca, | PC3 |
| 6427- | FEO, | Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma |
| - | vitro+vivo, | HCC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:404 Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid